Fujifilm Biotechnologies inaugurated its expanded Teesside campus in the UK, launching what the company calls the largest single-use CDMO facility in Britain after a roughly £400 million ($545 million) investment. The site adds 2,000 L and 5,000 L single-use bioreactors and up to 19,000 L of antibody manufacturing capacity, plus a Bioprocess Innovation Centre for high-throughput and continuous process development. Fujifilm said the 110,000 sq. ft. manufacturing facility will be operational in the first half of 2026 and will align with the company’s global kojoX modular platform to streamline technology transfers. The expansion expands mid-scale manufacturing options for biologics sponsors and strengthens regional drug supply-chain resilience for oncology, neurodegenerative, and rare-disease programs.